Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages

• Tipo: Artigo em Revista Científica Internacional
• Data: 2018

Autores

Vieira, ACC (Autor) Outra; Chaves, LL (Autor) Outra; Pinheiro, M (Autor) Outra; Costa Lima, SAC (Autor) Outra; Ferreira, DC (Autor) FFUP; Sarmento, B (Autor) Outra; Salette Reis (Autor) FFUP

Revista

Título: Artificial Cells, Nanomedicine and Biotechnology

Vol. 46

Páginas: S653-S663

ISSN: 2169-1401

Editora: Taylor & Francis

Indexação

ISI Web of Knowledge - 10 Citações

Scopus - 24 Citações

Outras Informações

ID Authenticus: P-00N-KH5

DOI: 10.1080/21691401.2018.1434186

Abstract (EN): Tuberculosis (TB) is still a devastating disease and more people have died of TB than any other infectious diseases throughout the history. The current therapy consists of a multidrug combination in a long-term treatment, being associated with the appearance of several adverse effects. Thus, solid lipid nanoparticles (SLNs) were developed using mannose as a lectin receptor ligand conjugate for macrophage targeting and to increase the therapeutic index of rifampicin (RIF). The developed SLNs were studied in terms of diameter, polydispersity index, zeta potential, encapsulation efficiency (EE) and loading capacity (LC). Morphology, in vitro drug release and differential scanning calorimetry studies, macrophage uptake studies, cell viability and storage stability studies were also performed. The diameter of the SLNs obtained was within the range of 160-250nm and drug EE was above 75%. The biocompatibility of M-SLNs was verified and the internalization in macrophages was improved with the mannosylation. The overall results suggested that the developed mannosylated formulations are safe and a promising tool for TB therapy targeted for macrophages.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 11